centres across Germany and Austria were included. At baseline, 62.6% were previously-treated with BoNT-A. The major primary components of CD were torticollis (64.5%) and torticaput (17.6%). Previously-treated patients showed a slight reduction of the Tsui scores, whereas BoNT-A-naïve patients had a more severe baseline Tsui score and improved much more over all cycles. Results were similar for CDQ-24. Interestingly, improvements mainly occurred in the Tsui subscore A (amplitude of sustained posture). Marked differences between CD subtypes regarding effectiveness could not be determined. To our knowledge this is the first large multi-centre study investigating the effectiveness of BoNT-A in different primary subtypes of CD over several injection cycles.
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Introduction
Cervical dystonia (CD) is a widespread form of focal dystonia with an estimated overall prevalence of 50 cases per million [1] . (between C3 and C7 or above C3 respectively) thus affecting different groups of muscles and influencing treatment strategy [2, 3] .
Botulinum neurotoxin type A (BoNT-A) is used for targeted muscle relaxation in various diseases, such as focal dystonias and spastic movement disorders [4, 5] . Since efficacy and safety of BoNT-A for the treatment of CD has been demonstrated in multiple randomised placebo-controlled trials [6] [7] [8] [9] , ACCEPTED MANUSCRIPT
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international practice guidelines recommend BoNT-A as first-line treatment for CD [10] . Furthermore, a large open prospective study confirmed safety and effectiveness of the BoNT-A abobotulinumtoxinA (aboBoNT-A) in treatmentnaïve patients presenting with heterogeneous forms of CD, when using a standardised regimen that allows tailored dosing based on individual symptom assessment [11] . In addition, improvements in quality of life up to 12 weeks after injection were observed [12, 13] . However, data on the long-term use of
BoNT-A or on its use in previously-treated patients are scarce, especially in a real-world setting. Hence, the present study was conducted to investigate the effectiveness of aboBoNT-A in BoNT-A-naïve as well as in previously-treated patients with CD over 12 months in a real-world non-interventional setting following the clinical routine. Analyses included stratification by primary component of CD (torticollis, torticaput, laterocollis or laterocaput).

Material and methods
Study design and patients
This was a prospective, open-label, non-interventional multi-centre postmarketing surveillance study, conducted at 41 sites in Germany and Austria (NCT01840462 Patients could be either naïve to BoNT-A (BoNT-A-naïve) or previously-treated with BoNT-A (previously-treated) on a regular basis for at least 2 years prior to inclusion whereby the last aboBoNT-A injection was between 3 and 6 months prior to inclusion. Patients were excluded if they suffered from anterocollis or retrocollis as primary component. All patients were required to provide their written informed consent prior to enrolment. The observation period comprised 12-16 months, including 5 visits.
Study treatment
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The decision to prescribe aboBoNT-A was made by the treating physician independently from the decision to enrol the patient and in accordance with the locally applicable Summary of Product Characteristics (SmPC). Study visits included an inclusion visit (V1) and three follow-up visits (V2, V3 and V4) 3 to 4 months, 6 to 8 months and 9 to 12 months, respectively, after V1. A last visit at the end of the study (V5) was scheduled approximately 12 weeks after V4.
The V1 (baseline) procedures included obtaining informed consent, eligibility check, review of demographics, medical history (including CD history and concomitant diseases) and previous CD treatment with BoNT-A, determination of primary and secondary component of CD, assessment of TSUI score and QoL (CDQ-24) as well as treatment with aboBoNT-A. The V2 to V4 procedures included assessment of TSUI score, treatment with aboBoNT-A and reason(s) for discontinuation, if applicable. At V3 the QoL (CDQ-24) was reported, too.
The V5 procedures included assessment of TSUI score and QoL (CDQ-24) and reason(s) for discontinuation. All of the procedures performed at these visits were in accordance with routine clinical practice. To ensure that data collected reflect the current clinical practice, the investigators were free to choose the targeted muscles, dosage, and the number of injection sites. In accordance with the SmPC, the injections of aboBoNT-A were expected to take place every 3-4 months.
Assessments
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The primary objective was to evaluate the effectiveness of aboBoNT-A in CD after 2 injection cycles in BoNT-A-naïve and previously-treated patients (V3 compared to V1 (baseline)). Effectiveness was measured by the change of severity of CD on the validated Tsui rating scale. The Tsui score (0-25 points) measures functional aspects of CD (amplitude of rotation, deflection and ante-/ retrocollis (subscore A), the duration of movement (subscore B), severity and duration of shoulder elevation (subscore C), severity and duration of tremor (subscore D), whereby a high score reflects a severe condition [14] . Secondary objectives included the effectiveness measures at each visit compared to baseline (V2, V4, V5). Moreover, quality of life (QoL) was assessed using the Craniocervical Dystonia Questionnaire CDQ-24 at baseline, V3 (after 2 injection cycles) and end of study (V5). The CDQ-24 (range from 1-100; 100 reflecting the worst possible QoL) is a disease-specific QoL instrument designed to demonstrate the influence of an intervention on the QoL in CD patients, taking account of stigma, emotional well-being, pain, activities of daily living, and social / family life [15] . Adverse events were documented continuously throughout the study.
Safety assessment
Adverse Events were not collected in the clinical database. Investigators were asked to report any related adverse event (AE) to the product, non-serious or
ACCEPTED MANUSCRIPT
A C C E P T E D M A N U S C R I P T serious, and any not related serious AE independent of the circumstances or suspected cause. The AE reports were sent by the investigator to the pharmacovigilance department. Safety data collected were reviewed as part of signal detection.
Statistical analyses
Descriptive statistical analysis of all collected data was performed using SAS 
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between-group treatment differences of the adjusted means (least square means)
were provided from the ANCOVA model.
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Results
Patient disposition and demographic characteristics
In total, 361 patients from 41 sites were enrolled in the study. One patient did not receive any aboBoNT-A injection and 59 withdrew from the study prematurely. The reasons for withdrawal are presented in Table 1 . The MAP, MMAP and CAP comprised 273, 233 and 236 patients, respectively. Baseline demographics for the MAP are summarised in Table 2 . The majority of patients of the MAP (176 patients (64.5%)) suffered from torticollis as primary CD component. Moreover, the MAP included 171 (62.6%) previously-treated and 102 (37.4%) treatment-naïve patients. Concomitant diseases were reported for 107 (39.2%) patients, most frequently hypertension (10.6%).
Treatment and dosing
Patients previously treated with BoNT-A had at baseline a mean ( aboBoNT-A dose via 578.7 ± 285.7 units at V2 to 625.6 ± 304.7 units at V4 for BoNT-A-naïve patients, resulting in comparable mean dose levels at V4 for previously-treated and BoNT-A-naïve patients (Figure 2 ).
Effectiveness results
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At baseline, the mean (±SD) overall total Tsui score was 6.4 ± 3.8. Similar Tsui scores were documented for patients with torticollis and torticaput (6.4 ± 3.8 and 6.5 ± 3.7 points) as primary component of CD, respectively. Patients with laterocollis and laterocaput as primary component of CD, respectively, had the lowest and highest mean values (5.7 ± 3.5 and 7.2 ± 4.6). BoNT-A-naïve patients had a considerable higher mean total Tsui score at baseline compared to previously-treated patients (7.8 ± 4.2 vs. 5.6 ± 3.3). Changes in the Tsui score from baseline during the study are shown in Figure 3 . Overall, the mean change of the total Tsui score from V1 to V3 (primary effectiveness variable) was -1.2 ± 3.4). There were no marked differences between primary components of CD (torticollis: -1.1 ± 3.6, torticaput: -1.4 ± 3.6, laterocollis: -0.9 ± 2.7, laterocaput: BoNT-A previous-treatment status revealed that differences between previouslytreated and BoNT-A-naïve subjects in the total Tsui score at V1 and in the change from V1 to V3 were primarily due to the Tsui subscore A (V1: 2.4 ± 1.4
vs. 3.6 ± 1.6; V3-V1: -0.1 ± 1.1 vs. -1.2 ± 1.7).
The mean (±SD) overall CDQ-24 total score at baseline was 32.5 ± 18.6. For all four primary components of CD the mean CDQ-24 total scores at V1 were of comparable size, ranging from 31.7 ± 18.5 for torticaput to 33.8 ± 17.0 for laterocaput. BoNT-A-naïve patients had a considerably higher mean CDQ-24 total score at V1 compared to previously-treated patients (38.4 ± 17.6 vs. 28.9 ± 18.2). Over the course of the study, the overall CDQ-24 total score decreased from baseline to V3 and V5 by 4. However, analyses by BoNT-A previous-treatment status showed that differences between previously-treated and BoNT-A-naïve patients in the CDQ-24 total score at V1 and subsequent changes from baseline are reflected in all ACCEPTED MANUSCRIPT
subscales, however less pronounced in the subscale social / family life ( Figure   6 ).
Results from the MMAP and CAP pertaining to changes in Tsui score, CDQ-24 score and dose modification were consistent with the MAP.
Safety results
In total, 15 of 361 patients experienced 31 adverse events (AEs) during the study. Seven of the patients experienced 11 serious adverse events; thereof 5
SAEs (2x dysphagia, 2x muscular weakness, 1x dyspnoea) were evaluated by the investigators as related to the study medication occurring in 2 patients. In these affected patients the dose was reduced or the treatment discontinued. 6
SAEs were evaluated (concussion, chest injury, fall, muscular weakness, septic shock, asphyxia) as not related. Three patients died during the study and were assessed as not related to aboBoNT-A and due to patient's concurrent medical conditions. Of the 20 non-serious AEs (11 patients), 13 AEs were evaluated by the reporter as related to the administration of aboBoNT-A. The most frequently reported adverse reactions were dysphagia (n=7) and local muscular weakness (n=5).
Discussion
ACCEPTED MANUSCRIPT
A C C E P T E D M A N U S C R I P T
This multicentre, non-interventional, prospective, longitudinal study investigated the effectiveness of aboBoNT-A injections over a period of 12-16 months in BoNT-naïve and previously-treated patients suffering from CD. To the best of our knowledge this was the first study to incorporate the collis/caput classification and to analyse all efficacy variables stratified by primary subtype of CD [2, 3] . The primary effectiveness variable was the difference of the Tsui score between baseline and visit 3 (3-4 months between each injection cycle) in
BoNT-A-naïve and previously-treated subjects, i.e. after two injection cycles with aboBoNT-A. The evaluation of the primary effectiveness variable showed a slight overall improvement of functional parameters of CD in the main analysis population (after 3-4 months after injection). When looking at the different primary components of CD, torticollis and -caput, laterocollis andcaput, there were no marked differences between these subgroups regarding the Tsui scale. However, caution should be observed with this interpretation because the Tsui score has been criticised for being unable to differentiate betweencollis and -caput types of CD [16] . At present, none of the available rating scales reflects this most current conceptual model of CD, indicating a need to develop a rating scale that describes all subtypes of CD [16] .
In contrast to the CD subtype, the previous-treatment status had a considerable impact on the change of the Tsui score from baseline to visit 3, which was reflected in the more pronounced change in BoNT-A-naïve compared to ACCEPTED MANUSCRIPT
previously-treated patients. Furthermore, the higher the Tsui score (i.e. the more severe the condition) was at start of therapy, the more it decreased during the observation period, indicating that the change of the Tsui score is mainly driven by the baseline Tsui score. This effect was mainly due to the BoNT-A-naïve patients. Those with more severe disease at baseline showed the largest improvement during the study, whereas those with a low baseline score did not improve more than previously-treated patients with a similar score. These results indicate that both groups benefit from the treatment with aboBoNT-A. The importance of individualised treatment with respect to primary CD subtype has been emphasised before [3, 11] . Two registry studies (ANCHOR-CD and CD-PROBE) have recently been published taking the CD subtypes into account [17, 18] . From another observational study (INTEREST IN CD2), baseline data have been reported [19] . Whereas these studies describe the primary CD subtypes within the cohort, to our knowledge, this study is the first to evaluate effectiveness over the different subtypes. When the classification of CD into caput and collis subtypes was introduced, new key muscles for BoNT-A injections were proposed, such as M. levator scapulae and M. obliquus capitis inferior [20] . The present study shows that these suggestions have been partly This study is limited by its non-interventional design which allows the identification of associations, but excludes the conclusion of causal relationships. The maximum effect of BoNT-A is usually occurring around 4 weeks post injection [7] meaning that 3-4 months after injection is already at a late stage of the treatment cycle, but due to the non-interventional design, the earlier time point could not be investigated here. The strength of this study is
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represented by the use of a validated score to measure the functional aspects of CD and a disease specific questionnaire for the assessment of QoL [14, 15] . Bias was minimised by enrolling patients in consecutive order rather than by physician's choice. Hence, the study provides a comprehensive view of the effectiveness of aboBoNT-A in the real world setting of CD in Germany and Austria.
Conclusion
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Data Sharing
Where patient data can be anonymised, Ipsen will share all individual participant data that underlie the results reported in this article with qualified researchers who provide a valid research question. Study documents, such as the study protocol and clinical study report, are not always available. Proposals should be submitted to DataSharing@Ipsen.com and will be assessed by a scientific review board. Data are available beginning 6 months and ending 5 years after publication; after this time, only raw data may be available.
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